Literature DB >> 20615487

Tumor-host cell interactions in the bone disease of myeloma.

Jessica A Fowler1, Claire M Edwards, Peter I Croucher.   

Abstract

Multiple myeloma is a hematological malignancy that is associated with the development of a destructive osteolytic bone disease, which is a major cause of morbidity for patients with myeloma. Interactions between myeloma cells and cells of the bone marrow microenvironment promote both tumor growth and survival and bone destruction, and the osteolytic bone disease is now recognized as a contributing component to tumor progression. Since myeloma bone disease is associated with both an increase in osteoclastic bone resorption and a suppression of osteoblastic bone formation, research to date has largely focused upon the role of the osteoclast and osteoblast. However, it is now clear that other cell types within the bone marrow, including cells of the immune system, mesenchymal stem cells and bone marrow stromal cells, can contribute to the development of myeloma bone disease. This review discusses the cellular mechanisms and potential therapeutic targets that have been implicated in myeloma bone disease.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20615487      PMCID: PMC3005983          DOI: 10.1016/j.bone.2010.06.029

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  106 in total

1.  High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.

Authors:  C Shimazaki; R Uchida; S Nakano; K Namura; S-i Fuchida; A Okano; M Okamoto; T Inaba
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

2.  Osteoblast stimulation in multiple myeloma lacking lytic bone lesions.

Authors:  R Bataille; D Chappard; C Marcelli; J F Rossi; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  Br J Haematol       Date:  1990-12       Impact factor: 6.998

3.  Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.

Authors:  O Hjertner; M L Torgersen; C Seidel; H Hjorth-Hansen; A Waage; M Børset; A Sundan
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

4.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Authors:  P I Croucher; C M Shipman; J Lippitt; M Perry; K Asosingh; A Hijzen; A C Brabbs; E J van Beek; I Holen; T M Skerry; C R Dunstan; G R Russell; B Van Camp; K Vanderkerken
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

5.  Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma.

Authors:  Michael G Alexandrakis; Constantina A Pappa; Spiros Miyakis; Aikaterini Sfiridaki; Maria Kafousi; Athanassios Alegakis; Efstathios N Stathopoulos
Journal:  Eur J Intern Med       Date:  2006-10       Impact factor: 4.487

6.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

7.  Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Authors:  Eline Menu; Evy De Leenheer; Hendrik De Raeve; Les Coulton; Takeshi Imanishi; Kazuyuki Miyashita; Els Van Valckenborgh; Ivan Van Riet; Ben Van Camp; Richard Horuk; Peter Croucher; Karin Vanderkerken
Journal:  Clin Exp Metastasis       Date:  2006-11-03       Impact factor: 5.150

8.  Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma.

Authors:  C Roux; P Ravaud; M Cohen-Solal; M C de Vernejoul; S Guillemant; B Cherruau; P Delmas; M Dougados; B Amor
Journal:  Bone       Date:  1994 Jan-Feb       Impact factor: 4.398

9.  Does myeloma secrete an osteoblast inhibiting factor?

Authors:  C E Evans; C S Galasko; C Ward
Journal:  J Bone Joint Surg Br       Date:  1989-03

Review 10.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

View more
  26 in total

1.  Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

Review 2.  Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.

Authors:  Michaela R Reagan; Lucy Liaw; Clifford J Rosen; Irene M Ghobrial
Journal:  Bone       Date:  2015-02-26       Impact factor: 4.398

Review 3.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

4.  Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

Authors:  Jessica A Fowler; Seint T Lwin; Matthew T Drake; James R Edwards; Robert A Kyle; Gregory R Mundy; Claire M Edwards
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

5.  Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy.

Authors:  Xuli Wang; Ye Yang; Huizhen Jia; Wanjian Jia; Scott Miller; Beth Bowman; Jun Feng; Fenghuang Zhan
Journal:  Biomater Sci       Date:  2014-04-14       Impact factor: 6.843

6.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

7.  A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Authors:  H Eda; L Santo; D D Cirstea; A J Yee; T A Scullen; N Nemani; Y Mishima; P R Waterman; S Arastu-Kapur; E Evans; J Singh; C J Kirk; W F Westlin; N S Raje
Journal:  Leukemia       Date:  2014-02-12       Impact factor: 11.528

Review 8.  Contributions of the host microenvironment to cancer-induced bone disease.

Authors:  Sam W Z Olechnowicz; Claire M Edwards
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

9.  Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Authors:  Song Xu; Kim De Veirman; Holly Evans; Gaia Cecilia Santini; Isabelle Vande Broek; Xavier Leleu; Ann De Becker; Ben Van Camp; Peter Croucher; Karin Vanderkerken; Ivan Van Riet
Journal:  Acta Pharmacol Sin       Date:  2013-04-08       Impact factor: 6.150

Review 10.  Multiple myeloma in the marrow: pathogenesis and treatments.

Authors:  Heather Fairfield; Carolyne Falank; Lindsey Avery; Michaela R Reagan
Journal:  Ann N Y Acad Sci       Date:  2016-01       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.